Loading clinical trials...
Loading clinical trials...
This is a randomized, open label intra-patient dose escalation study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of BPS804 in adults with osteogenesis imperfecta (OI). ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Ultragenyx Pharmaceutical Inc
NCT07366086 · Osteogenesis Imperfecta
NCT07412782 · Osteogenesis Imperfecta, Osteoporosis, and more
NCT04152551 · Osteogenesis Imperfecta
NCT05317637 · Osteogenesis Imperfecta
NCT03706482 · Osteogenesis Imperfecta
Novartis Investigative Site
Anaheim, California
Novartis Investigative Site
Miramar, Florida
Novartis Investigative Site
Brussels
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions